Literature DB >> 19793807

Evasion of the mucosal innate immune system by herpes simplex virus type 2.

Tao Peng1, Jia Zhu, Alexis Klock, Khamsone Phasouk, Meei-Li Huang, David M Koelle, Anna Wald, Lawrence Corey.   

Abstract

Understanding the mechanisms by which herpes simplex virus (HSV) evades host immune defenses is critical to defining new approaches for therapy and prevention. We performed transcriptional analyses and immunocytochemistry on sequential biopsy specimens of lesional tissue from the acute through the posthealing phases of recurrent mucocutaneous HSV-2 infection. Histological analysis of these biopsy specimens during the acute stage revealed a massive infiltration of T cells, as well as monocytes/macrophages, a large amount of myeloid, and a small number of plasmacytoid dendritic cells, in the dermis of these lesional biopsy specimens. Type I interferon (IFN-beta and IFN-alpha) was poorly expressed and gamma IFN (IFN-gamma) potently induced during time periods in which we detected abundant amounts of HSV-2 antigens and HSV-2 RNA. IFN-stimulated genes were also markedly upregulated, with expression patterns that more closely matched those in primary human fibroblasts treated by IFN-gamma than those in fibroblasts treated by IFN-beta. Transcriptional arrays of the same lesional biopsy sites during healing and at 2 and 4 weeks posthealing revealed no HSV nucleic acids or antigen; however, there was persistent expression of IFN-gamma, with very low levels of IFN-beta and IFN-alpha. The findings of extremely low levels of IFN-alpha and IFN-beta, despite the presence of a large number of cells capable of synthesizing these substances, suggest a potent alteration in host defense during HSV-2 infection in vivo. HSV-2's blockade of the innate immune system's production of type I IFN may be a major factor in allowing the virus to break through host mucosal defenses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793807      PMCID: PMC2786730          DOI: 10.1128/JVI.00939-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Cutting Edge: Plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ.

Authors:  Jennifer M Lund; Melissa M Linehan; Norifumi Iijima; Akiko Iwasaki
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts.

Authors:  Tao Peng; Jia Zhu; Yon Hwangbo; Lawrence Corey; Roger E Bumgarner
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

3.  Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling.

Authors:  Karen E Johnson; Byeongwoon Song; David M Knipe
Journal:  Virology       Date:  2008-02-14       Impact factor: 3.616

4.  Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses.

Authors:  Yutaro Kumagai; Osamu Takeuchi; Hiroki Kato; Himanshu Kumar; Kosuke Matsui; Eiichi Morii; Katsuyuki Aozasa; Taro Kawai; Shizuo Akira
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

5.  Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems.

Authors:  Simon B Rasmussen; Louise N Sørensen; Lene Malmgaard; Nina Ank; Joel D Baines; Zhijian J Chen; Søren R Paludan
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

6.  Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.

Authors:  Karen E Mark; Lawrence Corey; Tze-Chiang Meng; Amalia S Magaret; Meei-Li Huang; Stacy Selke; Herbert B Slade; Stephen K Tyring; Terri Warren; Stephen L Sacks; Peter Leone; Vicki A Bergland; Anna Wald
Journal:  J Infect Dis       Date:  2007-03-16       Impact factor: 5.226

7.  Expression of gamma interferon-dependent genes is blocked independently by virion host shutoff RNase and by US3 protein kinase.

Authors:  Li Liang; Bernard Roizman
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

8.  Herpes simplex virus encephalitis in human UNC-93B deficiency.

Authors:  Armanda Casrouge; Shen-Ying Zhang; Céline Eidenschenk; Emmanuelle Jouanguy; Anne Puel; Kun Yang; Alexandre Alcais; Capucine Picard; Nora Mahfoufi; Nathalie Nicolas; Lazaro Lorenzo; Sabine Plancoulaine; Brigitte Sénéchal; Frédéric Geissmann; Koichi Tabeta; Kasper Hoebe; Xin Du; Richard L Miller; Bénédicte Héron; Cyril Mignot; Thierry Billette de Villemeur; Pierre Lebon; Olivier Dulac; Flore Rozenberg; Bruce Beutler; Marc Tardieu; Laurent Abel; Jean-Laurent Casanova
Journal:  Science       Date:  2006-09-14       Impact factor: 47.728

9.  Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.

Authors:  Jia Zhu; David M Koelle; Jianhong Cao; Julio Vazquez; Meei Li Huang; Florian Hladik; Anna Wald; Lawrence Corey
Journal:  J Exp Med       Date:  2007-02-26       Impact factor: 14.307

10.  TLR3 deficiency in patients with herpes simplex encephalitis.

Authors:  Shen-Ying Zhang; Emmanuelle Jouanguy; Sophie Ugolini; Asma Smahi; Gaëlle Elain; Pedro Romero; David Segal; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Anne Puel; Capucine Picard; Ariane Chapgier; Sabine Plancoulaine; Matthias Titeux; Céline Cognet; Horst von Bernuth; Cheng-Lung Ku; Armanda Casrouge; Xin-Xin Zhang; Luis Barreiro; Joshua Leonard; Claire Hamilton; Pierre Lebon; Bénédicte Héron; Louis Vallée; Lluis Quintana-Murci; Alain Hovnanian; Flore Rozenberg; Eric Vivier; Frédéric Geissmann; Marc Tardieu; Laurent Abel; Jean-Laurent Casanova
Journal:  Science       Date:  2007-09-14       Impact factor: 47.728

View more
  33 in total

1.  Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells.

Authors:  Michael T Hensel; Tao Peng; Anqi Cheng; Stephen C De Rosa; Anna Wald; Kerry J Laing; Lichen Jing; Lichun Dong; Amalia S Magaret; David M Koelle
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

2.  An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection.

Authors:  Tao Peng; Jia Zhu; Khamsone Phasouk; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

3.  Changes in the soluble mucosal immune environment during genital herpes outbreaks.

Authors:  Marla J Keller; Rebecca P Madan; Gail Shust; Colleen A Carpenter; N Merna Torres; Sylvia Cho; Hnin Khine; Meei-Li Huang; Lawrence Corey; Mimi Kim; Betsy C Herold
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

Review 4.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

5.  The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Authors:  Joshua T Schiffer; Anna Wald; Stacy Selke; Lawrence Corey; Amalia Magaret
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

6.  HSV-2 inhibits type-I interferon signaling via multiple complementary and compensatory STAT2-associated mechanisms.

Authors:  Ravi-Kumar Kadeppagari; Rebecca L Sanchez; Timothy P Foster
Journal:  Virus Res       Date:  2012-05-23       Impact factor: 3.303

7.  Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.

Authors:  Christopher D Conrady; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

8.  Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.

Authors:  Briana Nixon; Martha Stefanidou; Pedro M M Mesquita; Esra Fakioglu; Theodore Segarra; Lisa Rohan; William Halford; Kenneth E Palmer; Betsy C Herold
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 9.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

10.  Innate defense mechanisms against HSV-1 infection in the target tissues, skin and brain.

Authors:  Yael Tsalenchuck; Israel Steiner; Amos Panet
Journal:  J Neurovirol       Date:  2016-04-20       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.